This post was originally published on sourceNEO’s Vision The developers of NEO are looking to spread blockchains across all of China. Their company, Onchain, has developed a Distributed Networks Architecture (DNA) to allow for the easy implementation and development of standardized blockchains. They want every interested field to easily be able to migrate their data and […]<br />The post NEO and Blockchains Across China appeared first on The Bitcoin News – Leading Bitcoin and Crypto News since 2012.
Hardforks in the Bitcoin system don’t surprise anyone anymore, but the Ethereum fork, carried out simultaneously with the ICO conducted by the e-Chat team is really something revolutionary for the entire crypto-community. The thing is that the project has long outgrown the limits of the usual blockchain-based messenger and transformed into an interesting, self-developing start-up. The e-Chat team decided to transform the messenger into a multi-functional platform where any participant or business can create their<br />Read More<br />The post e-Chat can conduct Ethereum Hardfork after the ICO appeared first on Bitcoinist.com.
Cowboy Ninja Viking, the long-awaited Chris Pratt comic book film about a covert agent with multiple personality disorder, has brought on Game of Thrones director Michelle MacLaren to helm the project. We’re glad to see a genuinely talented director chosen for a movie that’s had a lot of trouble getting off the ground.
MacLaren, who has an extensive TV resume—she’s worked on Westworld and The Walking Dead, to name a few—replaces World War Z director Marc Foster, who left the project back in 2015. Some names were tossed around in between, like John Wick’s directors David Leitch and Chad Stahelski. While MacLaren’s attached to another film at the moment (The Nightingale), The Hollywood Reporternotes that Cowboy Ninja Viking will likely wind up being her feature film debut. As such, it’s also her first comic book movie, though she came close before. You may recall she was previously set to direct Wonder Woman before Patty Jenkins came aboard, but left the project due to creative differences.
Based on Image’s comic book, by writer A.J. Lieberman and artist Riley Rossmo, Cowboy Ninja Viking centers on a counter-intelligence unit made up of patients with Multiple Personality Disorder. With the help of a psychotherapist, who uses psychiatric treatment, drugs, and past life regression therapy, they’re turned into agents known as Triplets—meaning they each have three different personalities inside their minds. Chris Pratt plays Duncan, a Triplet with the personalities and skills of a Cowboy, Ninja, and Viking. Other personality combos include Mohawk Indian-Playboy-Spartan, Amish-Demo Expert-Army Captain, and Sniper-Archer-Clothing Designer. After Duncan’s fellow Triplets leave the fold and become assassins, he’s tasked with hunting them down.
Cowboy Ninja Viking is a weird-enough concept, one that Disney was developing until it was deemed “too edgy,” and I was worried it would end up a subpar Split knockoff that doesn’t strive to portray multiple personality disorder (the more commonly accepted term is dissociative identity disorder, but the comic uses the other) fairly. But there are some signs it could be interesting. A 2014 report from Collider claims that all of Duncan’s personalities would be played by different actors, which sounds promising; I think any attempt to turn Pratt into a ninja would fall into Parks and Recreation Johnny Karate territory.
However, it’s hard to ignore that the film has been in and out of development hell over the course of eight years running. Disney bought the rights back in 2010, only to later drop it, as noted above, and Universal picked it up a few years later. Since then, it’s bounced between directors and writers, but it’s apparently set to come out June 28, 2019.
Life sciences startups in Asia are getting another boost with the $10 million investment in Engine Biosciences — a biotech company that’s applying machine learning to genomics for drug discovery. With its headquarters in both Singapore and San Francisco, the company has managed to attract some impressive investors from both the U.S. and Asia. The round was co-led by Danhua… Read More
Soon enough, U.S. grocery stores and pharmacies may carry a lot less of a popular over-the-counter anti-diarrhea drug. That’s the latest recommendation from the Food and Drug Administration (FDA), which is escalating its efforts to reduce the carnage of the opioid crisis.
On Tuesday, the FDA announced it would take steps to limit the public’s access to loperamide, an opioid and the active ingredient of Imodium AD along with other antidiarrheals. It is pushing manufacturers to change their packaging as well as lower the amount of doses available per product unit. This might include switching entirely to a blister pack model, where pills are individually wrapped, and ensuring that each product only contains a two-day supply. Currently, Imodium AD comes in both pill and liquid form, with pills sold in anything from a blister pack to a large bottle.
Ordinarily, loperamide only works on the digestive system, slowing it down temporarily. But in very high doses, it can also affect the central nervous system, just like the opioids people get addicted to. In recent years, the FDA and doctors have noticed people using loperamide—along with other drugs—to achieve a high; others have instead used it as a home remedy to stave off withdrawal symptoms, as an unapproved alternative to drugs like methadone.
Unfortunately, this experimentation isn’t particularly safe. There have been heart problems and even deaths linked to loperamide abuse. There’s no official data as to how often people are actually misusing loperamide, but it seems to have become more prominent in the wake of policies that have tried to limit the availability of other legal opioids. In 2016, the FDA issued a public safety advisory on loperamide. It also added a warning label concerning its heart risks to both prescription and over-the-counter drugs containing loperamide.
The packaging change isn’t the only one involving loperamide that the agency is seeking, either.
“I also plan to reach out to those who distribute loperamide online, through retail web sites, to ask them to take voluntary steps to help us address this abuse issue,” FDA chief Scott Gottlieb said in a statement Tuesday. “Today’s action is intended to change how the product is packaged, to eliminate these large volume containers. We know that many of the bulk purchases of these large volumes are being made online through major online web retailers.”
Johnson & Johnson, the manufacturers of Imodium AD, did not immediately respond to a request for comment regarding whether they would comply with the FDA’s recommendations.
Facebook’s dominance in digital advertising powered another surge in quarterly profit, though it said users were starting to shave back their time on its platform as it tries to address critics claims that the social network has harmful effects.